Johnson & Johnson gets FDA 510(k) clearance for updated MONARCH QUEST 3 system

Johnson & Johnson said it has received FDA 510(k) clearance for an update to its MONARCH QUEST 3 robotic bronchoscopy system, a step that expands the regulatory authorization for the company’s platform used to guide procedures inside the lung. The announcement comes as medical device makers increasingly look to software and AI capabilities to improve how clinicians plan and execute complex procedures.

The cleared MONARCH QUEST 3 update centers on enhancements to how the system helps clinicians plan, navigate, and visualize airways during bronchoscopy. According to the report, the update includes AI-powered functions designed to support procedure planning and navigation, and it also introduces upgrades related to imaging. In practical terms, those changes are aimed at improving the quality of guidance a physician receives in real time as the device is used to reach targeted areas within the bronchial tree.

The FDA 510(k) process is a regulatory pathway in which a device is reviewed to confirm it is substantially equivalent to a legally marketed predicate device, rather than requiring the same type of premarket approval that is used for certain higher-risk products. By clearing the update under 510(k), J&J is indicating that regulators view the changes as meeting the standards for safety and effectiveness based on the device category and comparison approach.

J&J did not, in the cited post, break out granular details such as the specific imaging improvements’ technical specifications, which AI functions are included, or whether the update applies to particular clinical use-cases, indications, or procedural steps within bronchoscopy. The report also does not specify whether the clearance changes labeling language, training requirements, or deployment timelines for customers already using the system.

MONARCH QUEST systems are positioned in the market for robotic bronchoscopy, where navigation and visualization are intended to help clinicians reach targets in the lung using image guidance and robotic-assisted control. The added emphasis on AI in this update reflects a broader industry trend in which device manufacturers try to translate software capabilities into workflow improvements, with the goal of making it easier for clinicians to plan access routes and maintain orientation while performing minimally invasive procedures.

For J&J, additional regulatory clearances can matter operationally even when the underlying device platform is already deployed, because updates often affect how customers evaluate the product. Software-and-imaging upgrades can also influence adoption decisions for hospitals that weigh performance improvements, physician training considerations, and the administrative work required to support new system configurations.

It is also notable that the report frames the update as an incremental advancement rather than a completely new platform, which may mean the company is building on an already cleared ecosystem. That matters in the bronchoscopy market, where procurement decisions may depend on continuity, interoperability, and how quickly clinical teams can incorporate new guidance features into everyday practice.

What remains unclear is the extent to which the AI features are tailored to specific imaging inputs, whether there are performance benchmarks disclosed for the new planning and navigation functions, and how the update will be positioned versus other robotic navigation and visualization systems on the market. The cited post does not provide clinical study results or reimbursement impact, so investors and customers will likely need to look for later documentation, labeling updates, or additional disclosures from the company.